Home Technology Chapter 2 Emerging technology in pharma and the role of AI and blockchain
Chapter
Licensed
Unlicensed Requires Authentication

Chapter 2 Emerging technology in pharma and the role of AI and blockchain

  • Rishabha Malviya , Shristy Verma , Sonali Sundram and Harshil Shah
Become an author with De Gruyter Brill
Explore this Subject How to publish with us
Digital Blockchain
This chapter is in the book Digital Blockchain

Abstract

The study, development, manufacture, and distribution of novel chemical entities (NCEs) and biological products intended to enhance human health constitute the core activities of the pharmaceutical industry, which follows a methodical and intricate business model. The chapter provides information about the innovative technologies introduced in pharma. In particular, drug discovery and regulatory approval are two areas where the pharmaceutical industry could undergo a radical transformation because of AI. Blockchain technology may significantly enhance the safeguarding of data confidentiality and the verification of intellectual property asset generation. Blockchain technology is also applicable to medical consultation frameworks, protecting users’ privacy and security, an essential consideration from the perspective of the patient when it comes to psychological and sexual diseases. Nonetheless, there are several obstacles that blockchain technology must overcome, including data management, privacy issues, data redundancy, and integration with current healthcare systems. An overview of the latest developments in artificial intelligence and blockchain technology is provided in the chapter.

Abstract

The study, development, manufacture, and distribution of novel chemical entities (NCEs) and biological products intended to enhance human health constitute the core activities of the pharmaceutical industry, which follows a methodical and intricate business model. The chapter provides information about the innovative technologies introduced in pharma. In particular, drug discovery and regulatory approval are two areas where the pharmaceutical industry could undergo a radical transformation because of AI. Blockchain technology may significantly enhance the safeguarding of data confidentiality and the verification of intellectual property asset generation. Blockchain technology is also applicable to medical consultation frameworks, protecting users’ privacy and security, an essential consideration from the perspective of the patient when it comes to psychological and sexual diseases. Nonetheless, there are several obstacles that blockchain technology must overcome, including data management, privacy issues, data redundancy, and integration with current healthcare systems. An overview of the latest developments in artificial intelligence and blockchain technology is provided in the chapter.

Chapters in this book

  1. Frontmatter I
  2. Preface V
  3. Foreword VII
  4. Contents IX
  5. Chapter 1 Introduction to smart pharma: foundation of AI and big data 1
  6. Chapter 2 Emerging technology in pharma and the role of AI and blockchain 19
  7. Chapter 3 Partnership and collaboration in the pharmaceutical industry 37
  8. Chapter 4 Education and training in smart pharma 55
  9. Chapter 5 Drug manufacturing and quality control with artificial intelligence 77
  10. Chapter 6 Drug development and clinical trial via artificial intelligence 97
  11. Chapter 7 AI-driven clinical decision support systems for pharma executives 121
  12. Chapter 8 AI-based pharmacovigilance and drug safety 143
  13. Chapter 9 Intellectual property and data privacy in the pharmaceutical sector 163
  14. Chapter 10 Regulatory affairs and compliance in the pharmaceutical sector 183
  15. Chapter 11 AI and big data in post-marketing surveillance 201
  16. Chapter 12 Challenges and ethical considerations 219
  17. Chapter 13 Future trends and innovations of AI in healthcare 237
  18. Index 253
https://doi.org/10.1515/9783111574288-002

Chapters in this book

  1. Frontmatter I
  2. Preface V
  3. Foreword VII
  4. Contents IX
  5. Chapter 1 Introduction to smart pharma: foundation of AI and big data 1
  6. Chapter 2 Emerging technology in pharma and the role of AI and blockchain 19
  7. Chapter 3 Partnership and collaboration in the pharmaceutical industry 37
  8. Chapter 4 Education and training in smart pharma 55
  9. Chapter 5 Drug manufacturing and quality control with artificial intelligence 77
  10. Chapter 6 Drug development and clinical trial via artificial intelligence 97
  11. Chapter 7 AI-driven clinical decision support systems for pharma executives 121
  12. Chapter 8 AI-based pharmacovigilance and drug safety 143
  13. Chapter 9 Intellectual property and data privacy in the pharmaceutical sector 163
  14. Chapter 10 Regulatory affairs and compliance in the pharmaceutical sector 183
  15. Chapter 11 AI and big data in post-marketing surveillance 201
  16. Chapter 12 Challenges and ethical considerations 219
  17. Chapter 13 Future trends and innovations of AI in healthcare 237
  18. Index 253
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 23.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/9783111574288-002/html
Scroll to top button